Search

hVIVO Signs Phase III Whooping Cough Vaccine Contract With ILiAD

hVIVO plc has signed a contract with ILiAD Biotechnologies to conduct the world's first pivotal Phase III human challenge trial for BPZE1, a next-generation whooping cough vaccine candidate. The trial will enrol over 500 healthy volunteers, representing hVIVO's largest human challenge trial to date. Revenue recognition is expected from H1 2026, with the majority recognised during 2026 and 2027, and the trial data will support future marketing applications to the FDA, MHRA, EMA and other global regulatory agencies.